ATE407695T1 - Tumorimpfstoff - Google Patents

Tumorimpfstoff

Info

Publication number
ATE407695T1
ATE407695T1 AT00902858T AT00902858T ATE407695T1 AT E407695 T1 ATE407695 T1 AT E407695T1 AT 00902858 T AT00902858 T AT 00902858T AT 00902858 T AT00902858 T AT 00902858T AT E407695 T1 ATE407695 T1 AT E407695T1
Authority
AT
Austria
Prior art keywords
tumor
vaccine
cytokine
tumor vaccine
prepared
Prior art date
Application number
AT00902858T
Other languages
English (en)
Inventor
Tadao Ohno
Bao Gang Peng
Kam Leong
Shu Qin Liu
Original Assignee
Riken
Cell Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riken, Cell Medicine Inc filed Critical Riken
Application granted granted Critical
Publication of ATE407695T1 publication Critical patent/ATE407695T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00902858T 1999-02-09 2000-02-09 Tumorimpfstoff ATE407695T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3119799 1999-02-09

Publications (1)

Publication Number Publication Date
ATE407695T1 true ATE407695T1 (de) 2008-09-15

Family

ID=12324707

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00902858T ATE407695T1 (de) 1999-02-09 2000-02-09 Tumorimpfstoff

Country Status (9)

Country Link
US (1) US7247310B1 (de)
EP (1) EP1159967B1 (de)
JP (1) JP5579586B2 (de)
CN (1) CN100425287C (de)
AT (1) ATE407695T1 (de)
CA (1) CA2362578A1 (de)
DE (1) DE60040213D1 (de)
HK (1) HK1041831B (de)
WO (1) WO2000047226A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR011700A0 (en) * 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
JP2002212099A (ja) * 2001-01-16 2002-07-31 Inst Of Physical & Chemical Res 腫瘍ワクチン
CA2478106A1 (en) * 2002-03-05 2003-09-12 Cell-Medicine, Inc. Solidified tissue immunoadjuvant
JP3492671B2 (ja) * 2002-04-18 2004-02-03 理化学研究所 免疫アジュバント
US20050129776A1 (en) 2002-05-03 2005-06-16 Inserm Microparticles supporting cells and active substances
EP1374893A1 (de) * 2002-06-17 2004-01-02 NovImmune S.A. Impfung mit Immuno-isolierten Zellen die einen Immunomodulator Produzieren
US20070081972A1 (en) * 2005-09-30 2007-04-12 The University Of Iowa Research Foundation Polymer-based delivery system for immunotherapy of cancer
US20090162405A1 (en) * 2006-12-14 2009-06-25 Yong Qian Proteinase-engineered cancer vaccine induces immune responses to prevent cancer and to systemically kill cancer cells
US9669082B2 (en) * 2005-10-03 2017-06-06 Yong Qian Proteinase-engineered cancer vaccine induces immune responses to prevent cancer and to systemically kill cancer cells
JP4238279B2 (ja) 2006-01-06 2009-03-18 セルメディシン株式会社 免疫アジュバント
US8283160B2 (en) * 2007-09-11 2012-10-09 Frey Ii William H Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system
US8741315B2 (en) 2007-09-12 2014-06-03 Yeda Research And Development Co. Ltd. Methods of treating tumors in immune-privileged sites
US9283266B2 (en) * 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
US8802076B2 (en) 2010-10-04 2014-08-12 Duke University Compositions and methods for modulating an immune response
CA2998991A1 (en) 2015-09-25 2017-04-20 Maxivax Sa Vaccination with immuno-isolated cells producing an immunomodulator
KR20190045912A (ko) 2016-09-06 2019-05-03 셀 메디신 가부시키가이샤 면역자극제
CN108114274B (zh) * 2017-12-26 2019-10-25 中国医学科学院生物医学工程研究所 一种基于肿瘤细胞为模板的肿瘤疫苗及其制备方法
US20210236694A1 (en) * 2018-05-03 2021-08-05 The Johns Hopkins University Induction of anti-tumoral immune microenvironments
WO2020255314A1 (ja) 2019-06-20 2020-12-24 セルメディシン株式会社 腫瘍ワクチン

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4338189A (en) * 1988-09-23 1990-04-18 University Of Southern California Immunotherapy vaccine for melanoma tumors
US5045320A (en) 1989-03-23 1991-09-03 Medical Biology Institute Large multivalent immunogen
HUT73383A (en) * 1993-03-19 1996-07-29 Boehringer Sohn Ingelheim Process for preparing cancer vaccines
EP0741580A4 (de) * 1993-12-14 2001-07-11 Univ Johns Hopkins Med Die kontrollierte freisetzung von pharmazeutisch aktiven substanzen in der immuntherapie
JP3680219B2 (ja) 1994-06-28 2005-08-10 独立行政法人理化学研究所 癌細胞障害性ｔリンパ球の誘導培養方法
WO1996001611A1 (en) * 1994-07-08 1996-01-25 Baxter International Inc. Implanted device containing tumor cells for the treatment of cancer
ATE229810T1 (de) 1996-10-11 2003-01-15 Univ California Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
JP4688254B2 (ja) * 1999-02-09 2011-05-25 独立行政法人理化学研究所 腫瘍ワクチン

Also Published As

Publication number Publication date
US7247310B1 (en) 2007-07-24
EP1159967A4 (de) 2002-07-10
EP1159967B1 (de) 2008-09-10
JP5579586B2 (ja) 2014-08-27
HK1041831A1 (en) 2002-07-26
DE60040213D1 (de) 2008-10-23
CA2362578A1 (en) 2000-08-17
WO2000047226A1 (en) 2000-08-17
CN1355709A (zh) 2002-06-26
CN100425287C (zh) 2008-10-15
JP2011046742A (ja) 2011-03-10
HK1041831B (en) 2009-05-22
EP1159967A1 (de) 2001-12-05

Similar Documents

Publication Publication Date Title
DE60040213D1 (de) Tumorimpfstoff
IL157443A0 (en) Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
IT1318649B1 (it) Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
TR200103575T2 (tr) Sülfonamid ve sülfamid ikameli/katkılı imidazokinolinler
TR200103574T2 (tr) Amid ikameli/katkılı imidazokinolinler
EP1409547A4 (de) Verfahren und pharmazeutische zusammensetzungen zur täuschung des immunsystems, insbesondere zur verwendung in der krebstherapie
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
AU2001294834A1 (en) Recombinant bcg vaccines for the prevention and treatment of cancer
IL164896A (en) Pharmaceutical compositions comprising immunoconjugates for the treatment of tumors
NO20015516D0 (no) Preparater og anvendelser av ET743 for behandling av kreft
KR100510795B1 (en) Compositions and Methods for the Treatment of Tumor
HUP0500424A2 (en) Combination therapy for the treatment of cancer
AU2001245295A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
PL351710A1 (en) Anti−inflammatory therapy for inflammatory mediated infection
AU2002313426A1 (en) Tumor antigens for prevention and/or treatment of cancer
DK1079818T3 (da) Præparat omfattende IL-18 og topotecan til behandling og/eller forhindring af cancer
NO20032597L (no) Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma
AU2001238493A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
PT1406859E (pt) Derivados substituídos de 4-aminociclo-hexanol
AU2002304883A1 (en) Device for the treatment of tumours
WO2002066492A3 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.
TR200101346T2 (tr) Rilüzol ve alfa-tokoferol bileşimi
AU2003206179A1 (en) An extract of acanthopanax koreanum for the treatment or prevention of hepatitis or the liver protective drug
AU2001245939A1 (en) Compositions and methods for the identification, assessment, prevention, and therapy of human cancers

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties